1. Predictive Biomarkers in Thyroid Cancer
   Elisabetta Macerola et al, 2022, Frontiers in Oncology CrossRef
2. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
   Marcia S Brose et al, 2021, The Lancet Oncology CrossRef
3. Actualización en carcinoma diferenciado de tiroides refractario a radioyodo
   E. Abou Jokh Casas et al, 2023, Revista Española de Medicina Nuclear e Imagen Molecular CrossRef
4. Radioactive iodine therapy: multiple faces of the same polyhedron
   Rosália do Prado Padovani et al, 2022, Archives of Endocrinology and Metabolism CrossRef
5. Update on iodine-refractory differentiated thyroid carcinoma
   E. Abou Jokh Casas et al, 2023, Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) CrossRef
6. Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies
   Giusy Elia et al, 2022, Expert Opinion on Pharmacotherapy CrossRef
7. Patient decision aids for patients with differentiated thyroid carcinoma: development process and alpha and beta testing
   Anna Koot et al, 2023, Frontiers in Endocrinology CrossRef
8. Molecular Genetics of Follicular-Derived Thyroid Cancer
   Elisabetta Macerola et al, 2021, Cancers CrossRef
9. Benefits of basil tea for patients with differentiated thyroid cancer during radioiodine therapy: A randomized controlled trial
   Kenta Nomura et al, 2023, Heliyon CrossRef
10. The role of ATP-binding cassette transporter genes in the metastatic process of epithelial thyroid carcinoma with aggressive behavior
    Giovanna Revilla et al, 2022, Unraveling the Complexities of Metastasis CrossRef